The Journal of Thoracic and Cardiovascular Surgery
Volume 136, Issue 1 , Pages 52-57 , July 2008

Deleterious outcome of No-React–treated stentless valved conduits after aortic root replacement: Why were Warnings ignored?

Received 22 August 2007 ,Accepted 11 September 2007.

References 

  1. Kouchoukos NT. Composite graft replacement of the ascending aorta and aortic valve with the inclusion-wrap technique and open technique. Semin Thorac Cardiovasc Surg. 1991;3:171–176
  2. Yacoub MH, Gehle P, Chandrasekaran V, Birks E, Child A, Radley-Smith R. Late results of a valve-preserving operation in patients with aneurysms of the ascending aorta and root. J Thorac Cardiovasc Surg. 1998;115:1080–1090
  3. David TE, Armstrong S, Ivanov J, Feindel C, Omran A, Webb G. Results of aortic valve-sparing operations. J Thorac Cardiovasc Surg. 2001;122:39–46
  4. Kouchoukos NT. Aortic allograft and pulmonary autografts for replacement of the aortic valve and aortic root. Ann Thorac Surg. 1999;67:1846–1848
  5. Carrel TP, Berdat P, Englberger L, Eckstein F, Immer F, Seiler C, et al. Aortic root replacement with a new stentless aortic valve xenograft conduit: preliminary hemodynamic and clinical results. J Heart Valve Dis. 2003;12:752–757
  6. Siniawski H, Lehmkuhl H, Weng Y, Pasic M, Yankah C, Hoffmann M, et al. Stentless aortic valves as an alternative to homografts for valve replacement in active infective endocarditis complicated by ring abscess. Ann Thorac Surg. 2003;75:803–808
  7. Albolhoda A, Yu S, Oyarzun J, McCormick J, Han S, Kemp F, et al. No-React detoxification process: a superior anticalcification method for bioprostheses. Ann Thorac Surg. 1996;62:1724–1730
  8. Albolhoda A, Sumei Y, Oyarzun J, McCormick J, Bogden J, Gabbay S. Calcification of bovine pericardium glutaraldehyde versus No-React biomodification. Ann Thorac Surg. 1996;62:169–174
  9. CE 0318 technical report. The NR-2000C stentless aortic valve conduit: a breakthrough in bioprosthetic design. Millburn (NJ): Shelhigh, Inc; USA.
  10. Siniawski H, Lehmkuhl H, Wenig Y, Pasic M, Yankah C, Hoffmann M, et al. Stentless aortic valves as an alternative to homografts for valve replacement in active infective endocarditis complicated by ring abscess. Ann Thorac Surg. 2003;75:803–808
  11. Akar AR, Szafranek A, Alexiou C, Janas R, Jasinski MJ, Swanevelder J, et al. Use of stentless xenografts in the aortic position: determinants of early and late outcome. Ann Thorac Surg. 2002;74:1450–1458
  12. Dearani JA, Orszulak TA, Schaff HV, Daly RC, Anderson BJ, Danielson GK. Results of allograft aortic valve replacement for complex endocarditis. J Thorac Cardiovasc Surg. 1997;113:285–291
  13. Grandmougin D, Prat A, Fayad G, Decoene C, Pol A, Waremboug H. Acute aortic endocarditis with annular destruction: assessment of surgical treatment with cryopreserved valvular homografts. J Heart Valve Dis. 1999;8:234–241
  14. Marianeschi SM, Iacona GM, Seddio F, Abella RF, Condoluci C, Cipriani A, et al. The Shelhigh No-React porcine pulmonary valve conduit: a new alternative to the homograft. Ann Thorac Surg. 2001;71:619–623
  15. Beck A, Thubrikar MJ, Robicsek F. Stress analysis of the aortic valve with and without the sinuses of Valsalva. J Heart Valve Dis. 2001;10:1–11
  16. Campbell EG, Gruen RL, Mountford J, Miller LG, Cleary PD, Blumenthal D. A national survey of physician-industry relationship. N Engl J Med. 2007;356:1742–1750
  17. Available at: http://www.fda.gov/foi/warning_letters/archive/m3695n.pdf. Accessed Aug 22, 2007.
  18. Available at: http://www.fda.gov/foi/warning_letters/archive/g5674d.pdf. Accessed Aug 22, 2007.
  19. FDA preliminary public health notification: possible contamination and malfunction of heart valves and valved conduits, annuloplasty rings, surgical grafts, meshes and other devices manufactured by Shelhigh, Inc. April 18, 2007. Available at: www.fda.gov/cdrh/safety/041807-shelhigh.html. Accessed Aug 22, 2007.
  20. Tjan TD, Klotz S, Schmid C, Scheld HH. Creation of a self-made total artificial heart using combined components of available ventricular assist devices. Thorac Cardiovasc Surg. 2008;56:51–53

 The Shelhigh NR-2000C is a totally biologic stentless conduit designed for the treatment of various aortic root pathologies. After implanting 115 conduits, 7 patients presented with disastrous findings, including aortic root rupture. Meticulous follow-up of those patients who already underwent implantation of this device has to be recommended.

 Thierry Carrel reports terminating a previous relationship with Shelhigh.

PII: S0022-5223(07)01692-3

doi: 10.1016/j.jtcvs.2007.09.047

The Journal of Thoracic and Cardiovascular Surgery
Volume 136, Issue 1 , Pages 52-57 , July 2008

Article Tools

* Image Usage & Resolution